In the extensive dispute over mRNA patents, CureVac has achieved a victory at the European Patent Office. The Opposition Division upheld two important patents in amended form. Parallel infringement
July, BioNTech's pending acquisition of GSK's cooperation partner CureVac has shifted the landscape. CureVac has now reached an agreement with BioNTech and Pfizer to end its patent proceedings. After
total 1 pages, 2 items